In one of these clinical trials (NCT02111850), patients received a cyclophosphamide plus fludarabine regimen and a lymphodepleting regimen that targeted MAGE-A3 TCR for patients with metastatic BC, cervical cancer, renal cancer, urothelial cancer, and melanoma. This evidence concerns the gene MAGEA3 and renal carcinoma.